Melanotan II: What the Research Actually Shows About the "Tanning Peptide"

Melanotan II is marketed as a shortcut to a tan without sun exposure — inject it, and skin darkens through the same melanin-production pathway UV light triggers, supposedly with less skin damage. It has never been approved by any regulator for any use, and it has never been tested in a completed human safety trial for tanning. What exists instead is a real, if scattered, body of case-report literature from dermatologists and other specialists who've treated people after they used it — and that literature is considerably more alarming than the marketing suggests. This article works through what's actually been documented, not what's claimed on the vendor sites selling it.

What Melanotan II Actually Is

Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH), the natural hormone that triggers melanocytes — the pigment-producing cells in skin — to produce more melanin. That is a real, well-understood mechanism: activating the melanocortin-1 receptor does darken skin. But α-MSH receptors aren't confined to skin. They're expressed in the brain and elsewhere in the body, which is why melanotan II's effects reach well beyond pigmentation — including, notably, sexual arousal pathways, which is the same receptor system the FDA-approved drug PT-141 (bremelanotide) targets for a completely different, regulated indication. We cover that approved side of the melanocortin story separately in PT-141 (bremelanotide): evidence and FDA status.

Only one α-MSH analog has ever been FDA-approved for any use: afamelanotide (brand name Scenesse), approved narrowly to increase light tolerance in adults with erythropoietic protoporphyria, a rare disorder that makes skin painfully light-sensitive — a specific medical indication, delivered as a controlled-release implant under a physician's care, nothing like a self-injected tanning regimen¹. Melanotan II is a different molecule, sold with no such approval, no such formulation control, and no such medical oversight.

The Melanoma Case Reports

This is the finding that should stop anyone considering melanotan II cold. Multiple independent case reports, published in peer-reviewed dermatology journals, describe melanoma developing in or near existing moles during or shortly after a person's melanotan use. A 2011 case report in the British Journal of Dermatology documented melanoma arising in a patient using melanotan². A separate 2012 case report in the Australasian Journal of Dermatology described melanoma in situ in another melanotan user³. These are individual cases, not a controlled trial — case reports establish that something happened in a specific patient, not that the drug definitively caused it in the epidemiological sense. But multiple independent dermatology teams, in different countries, publishing similar findings without coordinating with each other, is exactly the kind of signal that triggers a formal safety review — which is what happened next.

A 2017 review in the International Journal of Dermatology systematically examined the case literature on unregulated melanotan use, cataloguing four separate case reports of melanoma emerging from pre-existing moles during or shortly after melanotan use, plus additional reports of other melanocytic (mole-related) changes⁴. The review's own framing is careful — it states that conclusive causal evidence linking melanotan to melanoma is still lacking, because case reports can't establish causation the way a controlled trial can — but it also concludes that unregulated melanotan use carries real risk given uncertainties in preparation, dosing, and administration, and that multiple national health authorities have issued safety warnings as a result⁴. Separately, a well-documented phenomenon called "eruptive nevi" — the sudden appearance of new moles, or darkening of existing ones — has been linked to α-MSH-pathway activation in the dermatology literature independent of melanotan specifically⁵, which is mechanistically exactly what you'd expect from a drug that works by stimulating melanocyte activity.

The honest summary: nobody has run — or plausibly could ethically run — a randomized trial exposing healthy people to melanotan II and measuring melanoma incidence. What exists is a repeated, independently-observed signal from dermatologists treating real patients, converging with the drug's own mechanism (melanocyte stimulation), and a formal literature review that judged the pattern serious enough to warrant classifying illegal melanotan use as a genuine dermatologic risk rather than a fringe concern⁴.

Beyond the Skin: Priapism and a Kidney Injury Case

The melanoma signal isn't the only documented harm. A 2019 case report in BMJ Case Reports described a man who developed low-flow priapism — a prolonged, medically urgent erection requiring emergency intervention — after self-injecting melanotan subcutaneously for tanning⁶. The case required cavernosal aspiration and intracavernosal phenylephrine to avoid surgery, and the patient had not fully recovered erectile function at four-week follow-up⁶. The authors flagged it as a previously unreported complication of melanocortin-analog use worth documenting for anyone considering these drugs for any purpose⁶ — a real cost sitting on the opposite side of the same receptor system that gives PT-141 its approved libido effect.

Separately, a 2020 case report in CEN Case Reports described a patient who developed renal infarction — a blockage cutting off blood supply to part of a kidney — that the treating physicians linked to melanotan II use⁷. Again, a single case does not establish a population-level risk rate. But it adds to a pattern: multiple organ systems, multiple case reports, multiple countries, all describing serious, unexpected harms from a drug with no formal safety trial behind it.

No FDA Approval, and a History of Enforcement Action

Melanotan II has never been approved by the FDA for any purpose, including tanning. The FDA has taken enforcement action against companies marketing it: in 2007 the agency issued a warning letter to Melanocorp, Inc. over its illegal marketing of injectable Melanotan II, including claims that it protected against skin cancer — a claim regulators specifically rejected given the drug's unapproved status and the emerging melanoma signal⁸. That enforcement history means anyone buying melanotan II today is buying from an unregulated grey market with no independent verification of what's actually in the vial, compounding every risk described above with an unknown-purity, unknown-dose product. For what that unregulated-supply problem looks like across the peptide category generally, see peptide vendor red flags and scams and how to verify a peptide's COA and third-party testing.

Bottom Line

Melanotan II's core mechanism — activating melanocyte pigment production — is real, which is exactly why it darkens skin. But "the mechanism works" and "this is a safe way to get a tan" are different claims, and the second one has no trial evidence behind it at all. What exists instead is a repeated, independently-documented pattern of serious harm: melanoma arising in existing moles, eruptive new nevi, low-flow priapism requiring emergency treatment, and a case of kidney infarction — spread across multiple case reports in peer-reviewed dermatology and urology journals, converging with a mechanism that plausibly explains at least the skin findings. No regulator has approved melanotan II for any use, the FDA has taken enforcement action against companies selling it, and the only α-MSH analog ever approved (afamelanotide) is a narrowly indicated, physician-administered implant for a specific rare disease — nothing like the self-injected tanning product sold online. A tan that carries a documented melanoma signal is not a cosmetic shortcut; it's a trade that hasn't been shown to be worth making.